Thursday, 14 December 2017
Latest news
Main » What Does Institutional Ownership Look Like At AbbVie Inc. (ABBV)?

What Does Institutional Ownership Look Like At AbbVie Inc. (ABBV)?

08 December 2017

It has underperformed by 72.81% the S&P500.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 27th. Rodgers Brothers holds 2.96% in AbbVie Inc. (NYSE:ABBV). Warren Averett Asset Mgmt Ltd Liability Corp has 9,921 shares.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide.

AbbVie (ABBV) traded down $1.01 during midday trading on Wednesday, reaching $94.40. About 131,162 shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since December 6, 2016 and is uptrending. It has underperformed by 6.07% the S&P500. Of those analysts, 9 rate stock as a Strong Buy, 7 rate it as Hold, and just no analyst rates it as a Moderate Sell. Therefore 100% are positive. Icon plc had 30 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained AbbVie Inc. The rating was initiated by Societe Generale on Wednesday, April 6 with "Sell". BMO Capital Markets maintained the stock with "Market Perform" rating in Thursday, November 16 report. (NYSE:ABBV) has "Neutral" rating given on Monday, October 31 by Credit Suisse. The rating was initiated by Leerink Swann on Tuesday, October 18 with "Mkt Perform". The company was maintained on Friday, March 10 by Goldman Sachs.

More news: RSI suggests Twenty-First Century Fox, Inc. (FOXA)'s Stock Becomes Overbought

Abbvie Incorporated (NYSE:ABBV) had a decrease of 11.06% in short interest. The company was upgraded on Thursday, September 28 by Deutsche Bank. The company presently has a consensus rating of "Buy" and a consensus price target of $96.66. Middleton And Ma has invested 2.17% in AbbVie Inc. (NYSE:ABBV) on Thursday, May 25 with "Buy" rating. The rating was downgraded by Barclays Capital to "Equal-Weight" on Tuesday, December 1. (NYSE:ABBV) news were published by: Nasdaq.com which released: "AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan" on December 06, 2017, also Seekingalpha.com with their article: "AbbVie's risankizumab successful in fourth late-stage psoriasis study" published on December 04, 2017, Fool.com published: "The case for Johnson & Johnson" on November 21, 2017. Its up 0.01, from 0.99 in 2017Q1.

Motco increased its stake in shares of AbbVie Inc. It was reported on Dec, 7 by Finviz.com. Formidable Asset Management LLC lifted its position in shares of AbbVie by 0.3% during the second quarter. (ABBV) most recent 13F filing, the company has 118 new institutional holders - accounting for 10.23 million shares of its common stock. Manufacturers Life Ins The has invested 0.29% in AbbVie Inc. AbbVie Inc. The firm has a market capitalization of $152,315.39, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 1.35 and a beta of 1.52. (NYSE:ABBV) or 110,605 shares. Northeast Financial Consultants Inc invested in 2,920 shares. Mirador Cap Prns Ltd Partnership accumulated 0.83% or 19,173 shares. On the other side, investors are watching the first support level of $93.32. Point72 Asia (Hong Kong) owns 1,530 shares for 0.12% of their portfolio. The Ohio-based Camelot Portfolios has invested 0.19% in AbbVie Inc. Swiss National Bank now owns 5,823,829 shares of the company's stock valued at $422,286,000 after buying an additional 65,600 shares during the last quarter. Savant Capital LLC now owns 61,132 shares of the company's stock valued at $4,433,000 after buying an additional 793 shares in the last quarter. Moreover, Barbara Oil has 1.04% invested in AbbVie Inc. Abner Herrman & Brock LLC lifted its position in shares of AbbVie by 0.3% during the second quarter. Spdr Dow Jones Indl Avrg Etf U (DIA) was raised too. The shares were sold at an average price of $94.69, for a total transaction of $2,427,188.77. TRUE Private Wealth Advisors now owns 4,814 shares of the company's stock worth $349,000 after purchasing an additional 27 shares during the last quarter.

Several equities analysts recently issued reports on the company. Sales for the past 5 years for AbbVie Inc.is 8.00%.

A number of research firms have recently issued reports on ABBV. They expect $1.43 earnings per share, up 19.17% or $0.23 from last year's $1.2 per share. ABBV's profit will be $2.28 billion for 16.62 P/E if the $1.43 EPS becomes a reality. The company reported $1.28 EPS for the quarter, topping the consensus estimate of $1.26 by $0.02.

More news: Purchases New Position in CVS Health Corp (CVS)

Rutabaga Capital Management Llc increased Orchids Paper Products Company (TIS) stake by 46.22% reported in 2017Q2 SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. It dropped, as 89 investors sold QCOM shares while 481 reduced holdings.

Is QUALCOMM Incorporated (NASDAQ:QCOM) Cheap From Peers? St. Louis Trust Co grew its holdings in shares of AbbVie by 0.7% in the second quarter. Corporate insiders own 0.23% of the company's stock. Of those holders, 712 had increased positions amounting to 79.82 million shares, 903 had decreased positions amounting to 67.46 million shares, and 257 holders have a held position accounting for 978.38 million shares.

Clear Harbor Asset Management Llc holds 1.09% of its portfolio in New Jersey Resources Corporation for 141,772 shares. Lafleur And Godfrey Ltd Liability Corporation has 112,044 shares for 2.14% of their portfolio. Legal & General Group Plc now owns 8,049,351 shares of the company's stock worth $583,658,000 after acquiring an additional 131,159 shares during the period.

More news: The lowest paid celeb on I'm A Celeb has been revealed